Wells Fargo analyst Tiago Fauth raised the firm’s price target on Alnylam (ALNY) to $479 from $395 and keeps an Equal Weight rating on the shares. The firm believes it may be hard for Alnylam to outperform in 2026. Wells sees a more balanced risk/reward, as Amvuttra estimates seem priced in at these levels. Competition and pricing narratives could also weigh on the stock, keeping it range bound, the firm adds.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam announces results from post hoc analyses of HELIOS-B Phase 3 study
- Alnylam removed from US Conviction List at Goldman Sachs
- Alnylam Pharmaceuticals Reports Strong TTR Growth Amid Challenges
- Alnylam Pharmaceuticals Launches Promising Phase 3 Study on Nucresiran for hATTR-PN
- Alnylam price target raised to $500 from $490 at Oppenheimer